A Phase 3 interventional study of Inhaled treprostinil and Placebo inhalation solution in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 30 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-02.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2005, is one of 14 in phase 3, and was the 2nd registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2005.
This study's enrollment of 235 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 9th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2005, is one of 17 in phase 3, and was the 2nd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
Patients who have been on a stable dose of 125 mg twice daily (bid) of bosentan or any stable dose of sildenafil for at least three months prior to study start were randomized to either treprostinil inhalation solution or matching placebo.
Administration of study medication was performed by inhalation with the OPTINEB™ ultrasonic nebulizer.
The proposed dosing regimen was four times daily-upon awakening, at midday, evening (dinner time) and bedtime.
After a patient has completed the twelve-week study period, they were given the option of enrolling into an open-label extension study.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
This study's enrollment of 235 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
Drug: Inhaled treprostinil
Placebo inhalation solution for use in ultrasonic nebulizer
Drug: Placebo inhalation solution
Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
Also known as: Tyvaso
Doses are titrated to 9 breaths four times daily.
Also known as: Placebo
Peak 6-minute Walk Distance
Change in peak 6-minute walk distance from baseline to Week 12. Peak 6MWD was defined as a 6-minute walk test (6MWT) within 10 to 60 minutes after study drug inhalation
Time frame: 12 weeks
Clinical Worsening Events
Clinical worsening was defined as the first incidence of clinical worsening from randomization to the first occurrence of death, transplantation, hospitalization for PAH, or initiation of additional approved PAH therapy.
Time frame: 12 weeks
Borg Dyspnea Score
The Borg dyspnea score is a patient reported number between 0 (no perceived shortness of breath) and 10 (maximum perceived shortness of breath), obtained at the completion of each 6MWT.
Time frame: 12 weeks
New York Heart Association (NYHA) Functional Classification
Change in NYHA functional class at Week 12. NYHA classifications: Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
Time frame: 12 weeks
Trough 6MWD at Week 12
Change in 6MWD from Baseline to trough 6MWD at Week 12. Trough was defined as a 6MWT conducted at least 4 hours following study drug inhalation.
Time frame: 12 Weeks
Peak 6MWD at Week 6
Change in peak 6MWD between Baseline and Week 6.
Time frame: 6 weeks
Quality of Life (Minnesota Living With Heart Failure)
Quality of life as measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire was evaluated at baseline and at Week 12. The MLWHF questionnaire consists of 21 questions assessing how the patient's heart failure has prevented them from living the way they wanted during the defined time period. Each question was graded by the patient with a numeric value between 0 (No/none) and 5 (very much). These scores were then summed across the 21 questions for a Global Score. Global scores ranged from 0 to 105. These questions were further grouped into Physical (8 of the questions) and Emotional (5 of the questions) dimensions to further characterize the effect of heart failure on the patient's life. Physical scores ranged from 0 to 40, and emotional scores ranged from 0 to 25. For all 3 categories, the lower the score, the better the outcome. Values presented as change from Baseline.
Time frame: 12 weeks
Change in Signs and Symptoms of PAH
Signs and symptoms of PAH (Loud P2 sound, Ascites, Right ventricular S3 sound, Dyspnea, Right ventricular S4 sound, Orthopnea, Right ventricular heave, Dizziness, Murmur of tricuspid insufficiency, Syncope, Murmur of pulmonic insufficiency, Chest pain, Hepatomegaly, Palpitations, Jugular venous distension at 45 degrees, Fatigue, Edema) were assessed at Baseline and Week 12. The status of each sign and symptom ("absent" or "present") was assessed at each visit. To assess overall change from baseline in signs and symptoms, a "1" was assigned for each sign and symptom that was "present" at the Week 12 but was "absent" at baseline, a "-1" was assigned for each sign and symptom that was "absent" at Week 12 but was "present" at baseline, and a "0" was assigned for no change. An overall change score at each post-baseline assessment was then calculated by summing these values for all signs and symptoms. The overall change score had the potential to range from -17 to 17.
Time frame: 12 weeks
N-terminal Pro-B-Type Natriuretic Peptide (NT Pro-BNP)
Change in NT pro-BNP from Baseline to Week 12. Plasma samples were collected from patients at Baseline and Week 12 in order to measure any change over time in circulating plasma levels of this biomarker.
Time frame: 12 weeks
The first subject was enrolled on 7 June 2005 and the last subject exited the study on 12 Oct 2007.
| Milestone | Inhaled Treprostinil | Placebo |
|---|---|---|
| Started | 115 | 120 |
| Completed | 102 | 110 |
| Not completed | 13 | 10 |
Change in peak 6-minute walk distance from baseline to Week 12. Peak 6MWD was defined as a 6-minute walk test (6MWT) within 10 to 60 minutes after study drug inhalation
| meters | Inhaled Treprostinil | Placebo |
|---|---|---|
| Week 12 | 366.0 (300.0 to 423.0) | 360.0 (296.0 to 414.9) |
| Change from Baseline | 21.6 (-8.0 to 54.0) | 3.0 (-26.0 to 31.5) |
Clinical worsening was defined as the first incidence of clinical worsening from randomization to the first occurrence of death, transplantation, hospitalization for PAH, or initiation of additional approved PAH therapy.
| clinical worsening events | Inhaled Treprostinil | Placebo |
|---|---|---|
| Clinical Worsening Events | 4 | 6 |
The Borg dyspnea score is a patient reported number between 0 (no perceived shortness of breath) and 10 (maximum perceived shortness of breath), obtained at the completion of each 6MWT.
| score | Inhaled Treprostinil | Placebo |
|---|---|---|
| Week 12 | 3.68 ± 2.26 | 3.91 ± 2.33 |
| Change from Baseline | 0.0 ± 2.07 | 0.0 ± 1.72 |
Change in NYHA functional class at Week 12. NYHA classifications: Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
| participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| NYHA Class II | 22 (0 to 0) | 22 |
| NYHA Class III | 88 | 93 |
| NYHA Class IV | 5 | 5 |
Change in 6MWD from Baseline to trough 6MWD at Week 12. Trough was defined as a 6MWT conducted at least 4 hours following study drug inhalation.
| meters | Inhaled Treprostinil | Placebo |
|---|---|---|
| Week 12 trough | 364.0 (313.0 to 420.0) | 365.0 (289.0 to 422.0) |
| Change from Baseline | 12.4 (-10.0 to 51.3) | 0.8 (-17.9 to 25.0) |
Change in peak 6MWD between Baseline and Week 6.
| meters | Inhaled Treprostinil | Placebo |
|---|---|---|
| Week 6 Values | 375 (305 to 421) | 367 (292 to 419) |
| Change from Baseline | 21.6 (-4.0 to 51.8) | 3.0 (-16.5 to 22.0) |
Quality of life as measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire was evaluated at baseline and at Week 12. The MLWHF questionnaire consists of 21 questions assessing how the patient's heart failure has prevented them from living the way they wanted during the defined time period. Each question was graded by the patient with a numeric value between 0 (No/none) and 5 (very much). These scores were then summed across the 21 questions for a Global Score. Global scores ranged from 0 to 105. These questions were further grouped into Physical (8 of the questions) and Emotional (5 of the questions) dimensions to further characterize the effect of heart failure on the patient's life. Physical scores ranged from 0 to 40, and emotional scores ranged from 0 to 25. For all 3 categories, the lower the score, the better the outcome. Values presented as change from Baseline.
| units on a scale | Inhaled Treprostinil | Placebo |
|---|---|---|
| Global Score | -3.0 ± 18.7 | 0.0 ± 16.2 |
| Physical Dimension | -1.4 ± 8.9 | 0.0 ± 7.1 |
| Emotional Dimension | 0.0 ± 5.7 | 0.0 ± 5.7 |
Signs and symptoms of PAH (Loud P2 sound, Ascites, Right ventricular S3 sound, Dyspnea, Right ventricular S4 sound, Orthopnea, Right ventricular heave, Dizziness, Murmur of tricuspid insufficiency, Syncope, Murmur of pulmonic insufficiency, Chest pain, Hepatomegaly, Palpitations, Jugular venous distension at 45 degrees, Fatigue, Edema) were assessed at Baseline and Week 12. The status of each sign and symptom ("absent" or "present") was assessed at each visit. To assess overall change from baseline in signs and symptoms, a "1" was assigned for each sign and symptom that was "present" at the Week 12 but was "absent" at baseline, a "-1" was assigned for each sign and symptom that was "absent" at Week 12 but was "present" at baseline, and a "0" was assigned for no change. An overall change score at each post-baseline assessment was then calculated by summing these values for all signs and symptoms. The overall change score had the potential to range from -17 to 17.
| units on a scale | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in Signs and Symptoms of PAH | 0 ± 3.5 | 0 ± 2.5 |
Change in NT pro-BNP from Baseline to Week 12. Plasma samples were collected from patients at Baseline and Week 12 in order to measure any change over time in circulating plasma levels of this biomarker.
| pg/mL | Inhaled Treprostinil | Placebo |
|---|---|---|
| Week 12 | 377 (124 to 1091) | 756 (177 to 2213) |
| Change from Baseline | -57 (-396 to 34) | 40 (-93 to 288) |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Treprostinil | — | 9/115 (7.8%) | 101/115 (87.8%) |
| Placebo | — | 13/120 (10.8%) | 100/120 (83.3%) |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| Worsening PAHRespiratory, thoracic and mediastinal disorders | 3/115 | 2/120 |
| SyncopeNervous system disorders | 2/115 | 1/120 |
| AnemiaBlood and lymphatic system disorders | 1/115 | 0/120 |
| Abdominal painGastrointestinal disorders | 1/115 | 0/120 |
| Diabetes mellitusEndocrine disorders | 1/115 | 0/120 |
| DiarrheaGastrointestinal disorders | 1/115 | 0/120 |
| Gastric ulcerGastrointestinal disorders | 1/115 | 0/120 |
| right ventricular failureCardiac disorders | 1/115 | 0/120 |
| AnxietyNervous system disorders | 0/115 | 1/120 |
| Atrial flutterCardiac disorders | 0/115 | 1/120 |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| coughRespiratory, thoracic and mediastinal disorders | 62/115 | 35/120 |
| headacheNervous system disorders | 47/115 | 27/120 |
| nauseaGastrointestinal disorders | 22/115 | 13/120 |
| dizzinessNervous system disorders | 20/115 | 18/120 |
| flushingVascular disorders | 17/115 | 1/120 |
| throat irritationRespiratory, thoracic and mediastinal disorders | 16/115 | 10/120 |
| Upper respiratory tract infectionInfections and infestations | 10/115 | 14/120 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 13/115 | 7/120 |
| fatigueGeneral disorders | 10/115 | 12/120 |
| diarrheaGastrointestinal disorders | 11/115 | 9/120 |
| Age, Continuous(years) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Mean | 55 ± 13.1 | 52 (18 to 75) | 54 (18 to 75) |
| Sex: Female, Male(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Female | 93 | 98 | 191 |
| Male | 22 | 22 | 44 |
| Pulmonary Arterial Hypertension (PAH) Etiology(participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Idiopathic PAH (IPAH) | 64 | 67 | 131 |
| Connective Tissue Disease (CTD) | 40 | 37 | 77 |
| Other | 11 | 16 | 27 |
| Background PAH Therapy(participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Bosentan | 77 | 88 | 165 |
| Sildenafil | 38 | 32 | 70 |
| Time on Background Therapy(weeks) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Bosentan | 98 ± 79 | 90 ± 75 | 94 ± 77 |
| Sildenafil | 65 ± 60 | 77 ± 69 | 70 ± 64 |
| Baseline NYHA Class(participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Class III | 112 | 118 | 230 |
| Class IV | 3 | 2 | 5 |
| Baseline Six-Minute Walk Distance (6MWD)(meters) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Mean | 346 ± 63 | 351 ± 69 | 348 ± 66 |
The record gives a start of Jun 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →